The World’s Best-Selling Drug Just Lost a Key Patent Battle
"The rheumatoid arthritis and psoriasis medicine has recently been a target of biopharma companies that are trying to make generic Humira copycats called "biosimilars."...
Once the drug does fall off the patent cliff, however, AbbVie could be in for some rough times. Humira sales make up more than 60% of its revenues."
